Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Wong

Pain Medicine North Easton, MA Medical Doctor

NPI 1376665448 CMS profile 1171070

15 Roche Bros. Way, Orthopedic Care Specialists INC, North Easton, MA 02356

Open in the dashboard

General payments

$626

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Wong of North Easton, MA is reported in the CMS Open Payments database as having received $626 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 27th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77 3
2021 General $148 6
2020 General $154 8
2019 General $247 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Wong
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Anthony Wong were reported at $77. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Anthony Wong Pain Medicine median Middle half National median
2019 $247 $506 $144–$1,566 $163
2020 $154 $315 $96–$934 $114
2021 $148 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $0 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $77 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $447 31 payments
  2. Avanos Medical $75 1 payment
  3. Vertex Pharmaceuticals Incorporated $32 1 payment
  4. Globus Medical, Inc. $28 1 payment
  5. Abbott Laboratories $27 1 payment
  6. AbbVie, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $626 36 payments
Products named General payments · program years 2019–2025
  1. LYRICA $205 20 payments
  2. FLECTOR $84 5 payments
  3. GENERATOR $75 1 payment
  4. REYVOW $75 3 payments
  5. EMBEDA $75 6 payments
  6. FLECTOR PATCH $56 5 payments
  7. JOURNAVX $32 1 payment
  8. Senza $28 1 payment
  9. Proclaim IPG $27 1 payment
  10. BOTOX $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,168

Median for Anesthesiology: 322

Drug cost

$19,148

Median for Anesthesiology: $8,738

Branded share of claims

5.1%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 384 $5,559
Duloxetine Hcl Generic 209 $5,369
Pregabalin Generic 111 $2,122
Oxycodone Hcl Generic 82 $1,533
Tizanidine Hcl Generic 43 $661
Diclofenac Sodium Generic 57 $592
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $573
Baclofen Generic 22 $438
Morphine Sulfate Er Morphine Sulfate Brand 16 $413
Nortriptyline Hcl Generic 27 $391

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$242,954

Of which drugs: $339

Medicare patients

975

Average age 72

Services billed

5,576

637 women, 338 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Diabetes 30%
COPD 22%
Chronic kidney disease 21%
Ischemic heart disease 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 43 2,241 $219
Injection, methylprednisolone acetate, 40 mg J1030 Office 17 18 $81
Injection, gadobutrol, 0.1 ml A9585 Office 11 156 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record